The cancer profiling market reached approximately USD 10.5 billion in 2023 and is projected to grow at a CAGR of 12.3% through the end of the decade, reaching USD 23.2 billion by 2030. This expansion is driven by increased investments in cancer research and advancements in profiling technologies. The demand for point-of-care diagnostics is also creating significant opportunities across the industry.

Next-generation sequencing (NGS) is expected to experience the highest growth rate, driven by its effectiveness in identifying genetic alterations across various cancer types and its role in discovering potential biomarkers for early disease detection.

Breast cancer leads in terms of market share, supported by extensive research collaborations and its high global incidence rate. Biomarker discovery is a major revenue contributor due to its widespread application in drug development and the urgent need for effective cancer diagnostics amid rising global cancer burdens.

In the technique segment, proteomics holds a substantial share, enabling comprehensive profiling of protein levels in tumors to enhance disease understanding, staging, and treatment strategies.

Browse detailed report analysis: https://www.psmarketresearch.com/market-analysis/cancer-profiling-market

North America dominates the market, driven by the widespread adoption of biomarkers in drug development and the region's significant cancer prevalence. The presence of numerous global industry players further consolidates its leading position.

The Asia-Pacific (APAC) region is poised for the fastest growth, supported by increasing investments in healthcare, government initiatives, and rapid technological advancements in oncology research.

The rising global investment in cancer research continues to drive demand for cancer profiling, ensuring sustained growth in the coming years.